Trial Profile
A Phase II, Multicenter, Double-blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of Intravenous Natalizumab (300 mg) in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Receiving Concomitant Treatment With Methotrexate (MTX)
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Natalizumab (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Sponsors Biogen
- 09 Jun 2009 Primary endpoint identified as American College of Rheumatology 20 as reported by ClinicalTrials.gov.
- 09 Jun 2009 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 15 Feb 2007 Status change